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Neural crest cells (NCCs) are a transient, migratory cell population, which originates
during neurulation at the neural folds and contributes to the majority of tissues,
including the mesenchymal structures of the craniofacial skeleton. The deregulation of the
complex developmental processes that guide migration, proliferation, and differentiation
of NCCs may result in a wide range of pathological conditions grouped together as
neurocristopathies. Recently, due to their multipotent properties neural crest stem
cells have received considerable attention as a possible source for stem cell based
regenerative therapies. This exciting prospect underlines the need to further explore the
developmental programs that guide NCC differentiation. This review explores the particular
importance of ribosome biogenesis defects in this context since a specific interface
between ribosomopathies and neurocristopathies exists as evidenced by disorders such
as Treacher-Collins-Franceschetti syndrome (TCS) and Diamond-Blackfan anemia (DBA).
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INTRODUCTION
Neural crest cells (NCCs) are a diverse population of migratory
cells that give rise to most tissues during vertebrate development.
Defects in NCC generation, migration, and differentiation are the
underlying cause of a wide range of complex disorders known
a neurocristopathies. In addition, NCCs to some extent, bear
the major characteristics of stem cells including multipotency
and self-renewal. Recent efforts have focused on the possibil-
ity of using neural crest-derived mesenchymal stem cells for
regenerative purposes to address a plethora of degenerative dis-
orders and injuries to tissues with limited capacity for repair and
renewal. The regenerative use of these cells may become particu-
larly important for disorders of the brain and skull. Consequently,
a more thorough understanding of the extrinsic and intrinsic
control mechanisms guiding NCC renewal and fate determina-
tion is needed before therapeutic approaches become applicable.
Intriguingly, disorders caused by defects in ribosome biogenesis,
also known as ribosomopathies, often affect specifically neural
crest-derived tissues posing interesting questions as to the par-
ticular significance this basic cellular function holds for the NCC
lineage.
CLINICAL OVERVIEW OF NEUROCRISTOPATHIES
During development of the human embryo, NCCs arise between
the third and fifth weeks of gestation within the neural folds that
separate the ectoderm from the neural plate (see Figure 1 for
brief overview) (Etchevers et al., 2006). In the mouse, the mam-
malian model for neural crest development, the period of NCC
generation ranges from embryonic day (E)7 to E11. The neural
crest is a transient structure, with its cells undergoing an epithe-
lial to mesenchymal transition (EMT), subsequent migration to
a myriad of destinations, and eventual differentiation into many
different cell types. The neural crest progenitor cell population
gives rise to structures that are as diverse as neurons of the sen-
sory and autonomic nervous systems, pigment containing cells
of the epidermis, smooth muscle cells, as well as the bone, carti-
lage and connective tissue of the face and skull (Le Lievre and Le
Douarin, 1975; Sauka-Spengler and Bronner-Fraser, 2008). The
final fate of NCCs results from the interactions of a complex set
of extrinsic signals with the internal environment of the cells,
which can change during development in order to alter sensitivity
to these extrinsic signaling factors (Gammill and Bronner-Fraser,
2002; Sauka-Spengler and Bronner-Fraser, 2008). For example,
truncal NCCs, when transplanted at the vagal level will perform
and differentiate into enteric neurons just as vagal NCCs, how-
ever they will release acetylcholine rather than catecholamines
(Le Lievre and Le Douarin, 1975). Interestingly, NCCs that make
up the structures of the head, face and jaw, appear to have some
intrinsic properties, which are applied by the rostral endoderm,
before they set out on their migration (Couly et al., 2002; Creuzet
et al., 2002; Ruhin et al., 2003; Schneider and Helms, 2003). For
example, patterning of the hyoid cartilage and the fate of cephalic
NCCs depend on signals arising from the endoderm of the ventral
foregut (Couly et al., 2002; Ruhin et al., 2003).
Neural crest disorders, known as neurocristopathies, are the
result of aberrant proliferation, migration, differentiation, sur-
vival or any combination thereof of NCCs and lead to hypoplasia
of organs and tissues precipitating a wide range of patholog-
ical conditions. The term “neurocristopathy” was first coined
by Bolande in order to accentuate the commonalities of diverse
afflictions (Bolande, 1997). Neurocristopathic hypoplastic mal-
formations include many of the most common human birth
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FIGURE 1 | Neural crest formation and migration during
development. Neural crest regionalization (top) at the boundary of
the neural plate and epidermis is a multi-step process. First, the
border of the neural plate is set via secretion of neural plate
inductive signals (Fgf, Bmp, and Wnt) from the ventral ectoderm
and paraxial mesoderm (not shown). Anteriorly, the timing of Bmp
and Wnt signaling contributes toward setting the boundaries
between epidermis, prospective neural crest, and neural plate. In
the narrow band, where Wnt signaling induces Bmp signaling and
Wnt signaling is not subsequently turned off, NCCs are formed.
Bmp, Wnt, and Fgf, which are secreted by the prospective neural
crest, induce the expression of border regionalization genes such
as Msx1/2, Pax3/7, and Zic1. In contrast, in the epidermis high
concentrations of Bmp induce the expression Msx1/2, which
promote keratin expression and Dlx3/5, which induce Zic1 and Sox2
expression. Neural crest specification (middle) starts with the
expression of FoxD3, Slug/Snail, c-Myc, Sox9, and Id by the border
cells, which prevents this region from becoming either neural plate
or epidermal tissue. EMT, delamination, and migration of NCCs
(bottom), is primarily induced by FoxD3, Snail, and Sox9. These
factors are also capable of inducing a cranial neural crest fate for
cells of the lateral neural tube, when ectopically expressed in this
region. After delamination NCCs migrate to their respective
destinations, regulated by the expression of proteins such as
FoxD3, SoxE, Cad6/7, Nrp, and Eph receptors. Specifically, the head
and facial structures are largely products of the cranial neural
crest, which is a mixed population of cells, with about 10% of
these cells being multipotent progenitor cells.
defects such as Hirchsprung disease, cleft lip and/or palate,
and conotruncal heart malformations. On occasion, these disor-
ders can also show overlap with defects in neural tube closure.
Isolated neural tube closure defects are not considered neuro-
cristopathies, as closure events happen prior to the formation of
NCCs. However, commonmechanisms may underlie both neural
tube closure defects and neurocristopathies.
Hirschsprung’s disease, which is named after Harold
Hirschsprung who reported the disorder in 1886, is a congenital
malformation, which affects ∼1 out of 5,000 children and is iden-
tified by the lack of enteric ganglia along a length of the intestine
(Butler Tjaden and Trainor, 2013). The enteric ganglia, which are
a component of the autonomic nervous system, include sensory
neurons, motor neurons, and interneurons of the gut, which
are critical for normal digestive processes and proper nutrition.
Due to ensuing nutritional deficits of fat-soluble vitamins, this
affliction was fatal until the 1940’s, when a surgical method was
first developed for restoring proper digestive function.
Waardenburg-Shah Syndrome is an exceedingly rare and
genetically heterogeneous condition, occurring in 1 out of
500,000 live births. Affected individuals show both abnormal pig-
mentation and sensorineural deafness (Etchevers et al., 2006).
The condition is caused by partial or complete loss of melanocytes
in the skin and the stria vascularis, which is required for
endolymph production and proper ion homeostasis in the scala
media of the cochlea (Kruger et al., 2002).
Orofacial clefting is the result of improper outgrowth or
fusion of the facial prominences and/or palatal shelves, which
are derived from the maxilla of the first pharyngeal arch.
Clinical examples of neurocristopathies that display facial cleft-
ing are Diamond-Blackfan anemia (DBA) and Treacher-Collins-
Franceschetti Syndrome (TCS) (Trainor, 2010; Horos and von
Lindern, 2012). TCS was first identified in 1900, and is character-
ized by hypoplastic development of the facial bones, especially the
maxilla, mandible, and the zygomatic complex (Poswillo, 1975).
In addition, TCS is often times associated with a cleft of the
secondary palate. DBA is a rare, inherited bone marrow failure
syndrome, characterized by normochromic macrocytic anemia,
reticulocytopenia and deficiency or absence of erythroid precur-
sors (Ito et al., 2010). Patients in roughly half of diagnosed cases
of DBA also display craniofacial malformations (Horos and von
Lindern, 2012). Intriguingly, the underlying molecular deregu-
lation in both disorders are defects in ribosome biogenesis and
the resultant inability of mutant cells to produce fully func-
tional ribosomal particles that can properly participate in protein
biosynthesis and cellular homeostasis.
Over the past 30 plus years however, the definition of neu-
rocristopathies has changed to include not only pathologies of
tissues directly derived from the neural crest, but also instances
where altered NCC development hinders development of tightly
associated tissues that are not themselves neural crest-derived,
such as the heart or thyroid (Etchevers et al., 2006). Furthermore,
syndromic neurocristopathies may display both tumorigenic and
hypoplastic components. For instance, several types of tumors
specifically associated with neurocristopathies, can occur with
one another or with the underlying neurocristopathic affliction
(Qualman et al., 1986; Jensen et al., 1993). One example of
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neurocristopathic tumors are neuroblastomas consisting of cells
that resemble undifferentiated mesenchymal NCCs and acquire
characteristics of neurofibromas or ganglioneuromas upon tumor
regression. Originating from sympathetic components, neurob-
lastomas are the most common pediatric extracranial tumors,
with very high rates of remission (∼90%) (Nakagawara, 2004).
Pheochromocytomas, derived from the chromaffin cells of the
adrenal medulla, are a hallmark of a number of neural crest
afflictions such as Hirschsprung’s disease. Melanoma and Merkel
cell carcinoma are cutaneous NCC cancers, which can be both
invasive and aggressive in nature. Malignant melanoma arises in
neural crest-derived melanocytes, which are distributed widely
throughout the body as well as being one of the last tissues to
differentiate, and can occur in any part of the skin, even without
sunlight exposure. Pediatric melanoma is extremely aggressive
and carries a high rate of metastasis. Merkel cells are found in the
basal epidermis and together with sensory afferents form light-
touch receptors. Merkel cells can give rise to carcinomas and
have been shown to be neural crest derivatives even though a
recent study suggests an epidermal origin (Szeder et al., 2003;
Morrison et al., 2009). Merkel cell carcinomas are mostly local-
ized in the dermis of the head and neck region, with limited
spread over the body, and most commonly in the elderly. Merkel
cell carcinomas are shown to associate with neurofibromatosis,
breast and ovarian adenocarcinomas, as well as squamous cell
carcinomas. Medullary thyroid cancers are also considered to be
neurocristopathic tumors and can be diagnosed at all ages. In
addition to the several types of isolated tumors associated with
neurocristopathies, there are also a number of more complex
tumor predisposition syndromes, such as neurofibromatosis I
(von Recklinghausen disease), multiple endocrine neoplasias type
2A and 2B, familial medullary thyroid carcinoma, Stuge-Weber
syndrome and neurocutaneous melanosis (Etchevers et al., 2006).
MOLECULAR BASIS OF NEUROCRISTOPATHIES
INDUCTION
The roles of Wnt, Fgf, Bmp, and Shh signaling families in neural
crest induction/specification as well as their control by Hox tran-
scription factor expression and retinoic acid gradients have been
extensively studied and outlined (Duprez et al., 1999; Bastidas
et al., 2004; Lewis et al., 2004; Cheung et al., 2005; Monsoro-Burq
et al., 2005). Of particular importance to neural crest develop-
ment is also the expression of several transcription factors of
highly conserved families, such as Slug/Snail, Sox, Fox, and Pax
in the neural folds or in tissues surrounding the sites of neural
crest induction. In humans, mutations in PAX3, MITF, SNAI2,
and SOX10, have all been directly linked to syndromic neuro-
cristopathies (Dow et al., 1994; Pingault et al., 1998; Watanabe
et al., 1998; Sanchez-Martin et al., 2002). Slug/Snail homologues
are also expressed in the gastrulating mesoderm, and have been
implicated in EMT (Locascio et al., 2002; Wakahashi et al., 2013).
MIGRATION
The migration of NCCs is a long and complex process, which
starts with EMT, followed by delamination, and then migra-
tion along defined routes to various locations of the developing
embryo. Experiments in mice have shown that non-canonical
Wnt signaling viaWnt11 and its Frz7 receptor are required for the
initiation and maintenance of the migratory behavior of NCC.
Further, Sox9, Slug/Snail, Foxd3, and Sox10 also influence the
cell-autonomous acquisition of a migratory behavior by NCC
(Zhu et al., 2004; Cheung et al., 2005). The extracellular matrix,
and the respective expression levels of fibronectins, vitronectins,
laminins, and collagens further facilitate the migration of NCCs
as they travel further from the neural tube and begin to enter var-
ious compartments (Britsch et al., 1998; Davy et al., 2004; Zhu
et al., 2004; Pla et al., 2005).
DIFFERENTIATION
Naturally, the impressive variety of cell types generated by NCCs
and the multitude of tissues to which these cell types contribute
are both regulated by differentiation processes of great diversity
and complexity. Importantly, the fate of NCCs is dependent on
the intricate interactions between external stimuli and the inter-
nal environment of the cells. In addition, several factors have been
shown to dedifferentiate NCCs into multipotent cells in vitro,
which carries great significance for regenerative medicine and
presents a line of research, which will be certainly expanded in
coming years (Lee et al., 2007; Dupin and Coelho-Aguiar, 2013).
A thorough review of all processes involved in NCC differen-
tiation is beyond the scope of this article, but the three major
signaling cascades are described in brief.
Signaling pathways of the pigmentation lineage
In the presence of endothelin-3 (Edn3), NCCs have been shown
to differentiate into bipotent glia-melanocyte precursors and
tripotent melanocyte-neural-adrenergic precursor cells (Stone
et al., 1997; Dupin et al., 2000). Mutations of the endothelin
B receptor (Ednrb) gene in mice has been shown to produce a
recessive phenotype of spotting and megacolon, underlining the
importance of endothelins in pigmentation and development of
the gastrointestinal system (Hosoda et al., 1994). Mutations in
human EDNRB have been linked to type 4 Waardenburg-Shah
syndrome and Hirschsprung’s disease, depending on the exact
nature of the mutation (Puffenberger et al., 1994; Attie et al.,
1995). EDNRB signaling is transduced to the interior of the cell
via the Ras signaling pathway.
Signaling pathways of the neural lineages of the peripheral
nervous system
In Drosophila, the achaete-schute complex, which encodes basic
helix-loop-helix transcription factors, controls the development
of the nervous system by regulating the differentiation of ecto-
dermal cells into neuroblasts (Garcia-Bellido and de Celis, 2009).
The homologs of these genes in mice are Mash1 and Mash2
(Johnson et al., 1990; Parras et al., 2004). Mice with homozygous
Mash1 deletions die shortly after birth due to respiratory diffi-
culties and the inability to suckle (Guillemot et al., 1995; Parras
et al., 2004). These mice also lack parasympathetic and sympa-
thetic ganglia, and the enteric nerves of the esophagus. HASH1,
the human equivalent to Mash1, acts downstream of the PHOX2
transcription factors, which are expressed in all neurons in the
noradrenergic synthesis pathway at some point (de Pontual et al.,
2003; Pattyn et al., 2004).
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Signaling pathways of the cardio-cephalic lineages
While it was long suspected that deficiencies in NCCs resulted
in anomalies of the cardiac outflow tract and the caudal pharyn-
geal arches, it has recently been discovered that the pharyngeal
endoderm is also required for survival and fate determination of
cephalic NCCs (Couly et al., 2002). This appears to be due to the
release of retinoic acid by the adjacent mesoderm and concomi-
tant regulation of Hox gene activity, which determines rostrocau-
dal identity within surrounding cells and tissues (Halilagic et al.,
2003; Bohnsack et al., 2004). Further, the production of devel-
opmental signaling molecules such as sonic hedgehog (Shh) and
fibroblast growth factors (Fgfs) have also been implicated as con-
trolling the processes of cardiac and cephalic NCC differentiation
(Schneider et al., 2001; Abu-Issa et al., 2002).
RIBOSOME BIOGENESIS AND THE ROLE OF THE RIBOSOME
IN NEUROCRISTOPATHIES
Interestingly, the recently improved molecular understanding of
some neurocristopathies revealed a particular connection to ribo-
some biogenesis defects, which appear to particularly affect the
survival of NCCs and is reviewed below. Ribosome biogenesis
begins in the nucleus of eukaryotic cells when rRNA precur-
sor molecules associate with both pre-ribosomal and ribosomal
proteins (Venema and Tollervey, 1999). The entire process of
ribosome biosynthesis involves all three RNA polymerases and the
participation of well over 100 non-ribosomal proteins (Kressler
et al., 2010). After synthesis, which requires transcription by RNA
polymerase II, the ribosomal proteins are assembled in the cyto-
plasm and subsequently exported into the nucleus. As this is
happening, the 45S pre-rRNA transcribed by RNA polymerase
I undergoes a series of conformational changes and cleavages
to form the 18, 5.8, and 28S rRNAs. In contrast, the 5S rRNA
is independently transcribed by RNA polymerase III. The 18S
rRNA and 32 ribosomal proteins combine to form the 40S small
subunit, while the 5.8, 28, and 5S rRNAs combine with 47 ribo-
somal proteins to form the 60S large subunit. Both subunits are
then transferred to the cytoplasm for final assembly (Johnson
et al., 2002; Henras et al., 2008). Disruption of these processes
results in nucleolar stress, which commonly precipitates G1 cell
cycle arrest and cell death, via an increase in the activity of the
tumor-suppressor Tp53.
TCS syndrome and DBA are examples of well-characterized
syndromes that display craniofacial hypoplasia and orofacial cleft-
ing with the underlying causes involving defects in ribosome
generation (see Figure 2 for brief description). The Tail-short
mice can be added to these examples as an animal model with
midfacial clefting of partial penetrance (Morgan, 1950). TCS is a
heterogeneous disorder, which was initially shown to arise from
mutations in Treacle, a nuclear phosphoprotein, encoded by the
TCOF1 gene (Trainor et al., 2009). TCS causes dysplasia of the
craniofacial structures including the bones of the face, the palate,
external ear structures and the ear canals (Dauwerse et al., 2011).
The disorder results in disrupted craniofacial development due
to alterations in 28S ribosome biogenesis, and the resulting stabi-
lization and cellular enrichment of Tp53 due to nucleolar stress.
As a consequence, increased Tp53 levels lead to G1 cell cycle
arrest and specific apoptosis of neuroepithelial cells, which results
in hypoplastic neural crest-derived structures of the craniofacial
skeleton (Jones et al., 2008; Sakai and Trainor, 2009). More recent
work has identified cases of TCS in which human patients carry
FIGURE 2 | Aspects of the twomost prevalent and best-understood
neurocristopathies/ribosomopathies, Treacher Collins Syndrome and
Diamond-Blackfan anemia.At the top, the diagramdepicts known geneswith
causative mutations in the respective disorders. For more in depth reviews see
Trainor (2010), Dauwerse et al. (2011), Payne et al. (2012), and Boultwood et al.
(2013). The most-common symptoms are listed below. These symptoms may
appear isolated or more commonly in conjunction with the other symptoms.
Current treatments and approaches for ameliorating the effects of these
syndromes. For the commonly found craniofacial dysplasias only reconstructive
surgery is effectively used at this point. While leucine treatment has had
positive results in human patients, amino acid treatments come with a bevy of
side effects such as ketoacidosis, decreased blood sugar due to increased
insulin release by the pancreas, complications of lung function, and hepatic
encephalopathy. Recent studies in animal models have shown that Tp53
inhibition will at least partially rescue phenotypic deficiencies in TCS and that
Tp53 inhibition and leucine treatment reduce the severity of the effects of DBA.
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mutations in RNA polymerases I and III, providing further evi-
dence that TCS is a neurocristopathic ribosomopathy (Dauwerse
et al., 2011). Specifically, both heterozygous and homozygous car-
riers of mutant alleles in POL1RC and POL1RD were detected
that displayed symptoms of TCS but did not express the mutant
treacle protein (Dauwerse et al., 2011). Finally, it has been demon-
strated that both genetic and pharmacological inactivation of
Tp53 is capable of ameliorating the phenotypic defects associ-
ated with TCS via reduction of cyclin-G1 mediated cell cycle
arrest and a reduction in Tp53 driven cell death of NCCs (Jones
et al., 2008). Rescued mutants show improvements in craniofa-
cial morphogenesis as well as an extended lifespan compared to
their untreated counterparts. These improvements occur apart
from the deficits shown in ribosome biogenesis, which suggests
that Tp53 mediated cell cycle arrest is the primary pathological
mechanism in mice affected with TCS (Jones et al., 2008).
DBA is a disease caused by mutations in any one of sev-
eral ribosomal proteins, such as RPL15, RPL26, RPL35, RPL35a,
RPLP2, RPS14, and RPS19, which lead to an imbalance between
rRNA and ribosomal protein levels during construction of the
ribosome (Uechi et al., 2008; Devlin et al., 2010; Horos and
von Lindern, 2012; Landowski et al., 2013). Eventually, altered
ribosome biosynthesis and the resultant accumulation of free
ribosomal proteins leads to the stabilization and enrichment of
Tp53, decreased proliferation, and increased apoptosis in a variety
of tissues (Horos and von Lindern, 2012). DBA is an inher-
ited disease with its primary symptoms being normochromic
anemia, macrocytic anemia, diminished numbers of erythroid
progenitor cells in the bone marrow, and reticulocytopenia, or
decreased immature red blood cell count (Payne et al., 2012;
Landowski et al., 2013). A subset of patients also display hypoplas-
tic craniofacial structures, as well as malformations of the upper
limb, heart and urogenital tract (Landowski et al., 2013). It has
been demonstrated that haploinsufficiency of ribosomal proteins
Rps14 and Rps19 causes symptoms resembling DBA in zebrafish
such as anemia and craniofacial dysplasia, and also that treatment
with L-Leucine reduces the severity of both anemia and devel-
opmental deficits (Payne et al., 2012; Boultwood et al., 2013).
L-leucine induces protein synthesis primarily though induction
of the mammalian target of rapamycin complex 1 (mTORC1)
and the respective homologs in non-mammalian species. A con-
siderable volume of research has uncovered in great detail the
central role mTORC1 occupies in the regulation of cell growth
and survival, however the mechanism by which mTORC1 is reg-
ulated by amino acids such as L-leucine is just beginning to
be understood (Sengupta et al., 2010; Payne et al., 2012). The
activation of mTORC1 leads to phosphorylation of two target
proteins; eukaryotic translation initiation factor 4E-binding pro-
tein 1 (Eif4Ebp1), which is critical for cap-dependent mRNA
translation, and S6 kinase1 (S6K1), which promotes mRNA
translation via regulation of the proteins involved (Ruvinsky
and Meyuhas, 2006; Khanna-Gupta, 2011). It appears that in
Rps14- and Rps19-deficient zebrafish the Torc1 pathway becomes
activated upon nucleolar stress response (Payne et al., 2012). L-
leucine treatment in Rps14- and Rps19-deficient zebrafish causes
an increase in S6K1 phosphorylation compared to untreated ani-
mals, which already have higher than normal levels of S6K1
activity, meaning that over-activation of the Torc1 pathway is
likely necessary in order to overcome the deficiencies in these
animals (Payne et al., 2012). In human hematopoietic CD34+
stem cells, deletion of RPS14 and RPS19 cause Tp53 accumu-
lation specifically in erythroid progenitor cells, which results in
cell cycle arrest and apoptosis in specific cell types and this effect
can be reversed by inhibition of Tp53 activity (Dutt et al., 2011).
Perhaps most interestingly, increases in Tp53 activity have been
associated with significant decrease in S6K1 phosphorylation as
well as an increase in deactivation of Eif4Ebp1 via dephosphory-
lation (Horton et al., 2002; Dutt et al., 2011). However, mRNA
levels of Tp53 target genes remains unchanged during L-leucine
treatment, suggesting that the amino acid treatment acts outside
of the Tp53 pathway (Payne et al., 2012). Additionally, human
DBA patients of the same family carrying the same mutation can
present themselves with drastically different phenotypic effects,
further illustrating the complexity of the disease. While DBA
patients and animal models for DBA display deficits in neural
crest-derived structures, the molecular studies on its neurocristo-
pathic aspects have not yet been performed. Consequently, DBA
may be classified as a ribosomopathy with neurocristopathic
aspects.
Finally, recent research has confirmed that Tail-short (Ts+/−)
mice, which display a partially penetrant median facial cleft, carry
dominantmutations in the ribosomal protein Rpl38 (Kondrashov
et al., 2011).Moreover, this landmark study has clearly shown that
Rpl38 can mediate the selective translation of Hox mRNA tran-
scripts, intriguingly, providing the first evidence that ribosomal
proteins exert a regulatory function in the tissue-specific trans-
lation of certain mRNAs (Kondrashov et al., 2011). Specifically,
the detailed quantification of mRNA transcripts of Hox genes
revealed no changes in overall expression levels in the Ts mutants,
but certain Hox transcripts show significant changes in protein
levels in mutant animals. The study strongly suggests that cer-
tain Hox genes require normal Rpl38 functionality for proper
translation. Also, a genetic screen displays remarkable dynamic
regulation of the ribosomal proteins throughout the vertebrate
embryo during development, perhaps suggesting that tissue spe-
cific phenotypes, such as the ribosomopathies described here,
are the result of alterations in specific ribosomal associated pro-
teins required for translation of specific morphogenetic mRNAs
(Kondrashov et al., 2011).
CELL CYCLE REGULATION BY THE TP53-MDM2 LOOP
The processes of cell growth and proliferation are intrinsically
linked and both are highly dependent on proper protein syn-
thesis mediated by a functional ribosomal machinery. In tissues,
organs, and entire organisms, the maintenance of an appro-
priate cell number set by the proper balance of apoptosis and
proliferation is critical for correct function and survival. For
instance, the rate of proliferation is regulated at the level of
cell cycle progression, which is tightly controlled at each phase,
most notably at the G1/S transition point. In response to a vari-
ety of extracellular and intracellular signals, the cell can divide,
become quiescent, or even differentiate (Norbury and Nurse,
1992; Du and Stillman, 2002). Many types of tumorigenic can-
cers arise from loss of control at this checkpoint, often resultant
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of improper regulation of proto-oncogenes or tumor-suppressor
genes (Green and Evan, 2002; Vousden, 2002). For instance, the
tumor-suppressor protein TP53 plays a central role in the G1 to
S transition. Characteristically, mutations in TP53 are found in
more than 50% of all human cancers, and modulators of TP53
have been implicated in many other cancers. Notably, the MDM2
gene, which encodes a TP53 inhibitor, is altered in nearly 10%
of all non-TP53 originating cancer types (Kubbutat et al., 1997;
Momand et al., 1998; Toledo and Wahl, 2006). In the cell, TP53
levels are usually kept low, due to continuous degradation by the
E3-ligase MDM2, which tags TP53 for proteolysis by the protea-
some (Haupt et al., 1997; Honda et al., 1997). Further, MDM2
is transcriptionally activated by TP53, creating a self-regulating
negative feedback loop (Michael and Oren, 2003). During nucle-
olar stress, which may be triggered by a disruption in ribosome
biogenesis, MDM2 becomes inactivated by its association with
ribosomal proteins L5 and L11, and loses its ability to ubiquiti-
nate TP53 (Lohrum et al., 2003; Zhang et al., 2003; Dai and Lu,
2004). Consequently, TP53 levels increase within the cell leading
to G1 cell cycle arrest, apoptosis, or senescence. (Vogelstein et al.,
2000).
IS THERE A SPECIFIC SENSITIVITY OF THE NEURAL CREST
TO ABERRANT CELL CYCLE REGULATION AND ALTERED
RIBOSOME BIOGENESIS?
As outlined earlier, during EMT, migration, and differentiation
of NCCs, several signaling pathways integrate to properly reg-
ulate cellular behavior and fate determination. Defective ribo-
some biosynthesis will not only impair cell survival due to Tp53
mediated cell-cycle arrest and apoptosis, surviving cells will be
unable to produce new ribosomes as effectively thus limiting
their capacity for creating new proteins necessary for such tightly
orchestrated developmental events. It is conceivable that the spe-
cific program of EMT and long-range migration inherent to
NCCs, imposes a particular burden on these cells to command
a well-functioning biosynthetic machinery and thus a particu-
lar sensitivity to defects in ribosome biosynthesis. Intriguingly,
studies in the slime mold Dictyostelium, have demonstrated the
requirement for changes to the ribosomal protein profiles to tran-
sition cells from the multicellular fruiting body to unicellular
vegetative cells, providing a possible analog for developmental
changes that also govern NCCs (Ramagopal, 1992). Furthermore,
ribosomal expression screens have revealed a dynamic regulation
of the individual ribosomal proteins within the developing ver-
tebrate embryo, suggesting that heterogeneous ribosomal protein
populations are necessary for proper development of different tis-
sues and structures in vertebrates (Kondrashov et al., 2011). To
further explore these interesting questions, future studies may
focus on isolating NCCs of different states, such as premigra-
tory and migratory populations, using cell-sorting approaches
and compare the composition of preribosomal and ribosomal
proteins found in these cells. The fact that NCCs undergo rapid
developmental transitions and precise levels of required pro-
teins are needed for each step of the process, suggests that
alterations in the ability to rapidly manufacture for instance sig-
naling molecules or cytoskeletal components may have large-scale
consequences.
THE manta-ray MUTANT: A NOVEL MODEL FOR THE STUDY
OF RIBOSOMOPATHIES AND NEUROCRISTOPATHIES IN
MICE
The intricate and complex interactions between ribosome
biogenesis defects and neurocristopathies can be best elucidated
through the generation and analysis of suitable animal models.
Consequently, the search for such models has to be an impor-
tant component of future research efforts. Recently, we identified
in a forward genetic screen in mice a line with pronounced
craniofacial deficits inherited in an autosomal recessive pattern
(Zarbalis et al., 2004). The line was named manta-ray (mray)
due to its unique craniofacial morphology characterized by a
median cleft of the maxillae and secondary palate. The palatal
shelves of affected mutants elevate, but do not display proper out-
growth or fusion at the midline at E14.5. The nasal septum and
other facial midline structures are reduced in size, as are the fore-
brain, hindbrain, and the majority of other tissues and organs
of homozygous mray mutants. Positional cloning efforts revealed
the causative mutation in the gene encoding the WD-40 domain-
containing factor p21-activated kinase 1 inhibitory protein 1
(Pak1ip1) (Ross et al., 2013). Originally, the Pak1ip1 homo-
logue Skb15 was identified in fission yeast (Schizosaccharomyces
pombe) and characterized as a negative regulator of the p21-
activated kinase, Shk1 (Kim et al., 2001). P21 activated kinases
have been implicated in a myriad of cellular functions but are
most often associated with their roles in cell polarity and as
organizers of cytoskeletal assembly (Daniels and Bokoch, 1999;
Ong et al., 2011). Skb15 was shown to be essential for cytoskele-
tal regulation as well as coordinating the process of cytokinesis
(Kim et al., 2001). Perhaps most interestingly, it was shown that
mouse Pak1ip1 was able to serve as a functional substitute for
Skb15 in yeast cells, indicating that Pak1ip1 function remained
highly conserved in species separated by approximately 1.5 billion
years of evolution (Kim et al., 2001). Several years passed with-
out any significant advancement of knowledge on the function
of Pak1ip1 and its homologues, until a 2007 study characterized
Skb15 and its homologue in budding yeast (Saccharomyces cere-
visiae), Mak11, as 60S ribosomal assembly factors (Saveanu et al.,
2007). Mak11 was found in association with the pre-60S assembly
factor, Rlp24, an interaction that was strengthened when another
pre-60S factor, Nog11, was depleted (Saveanu et al., 2003, 2007).
Most importantly, the loss of Mak11 interfered with the matura-
tion of 60S rRNA, resulting in G1 cell cycle delay and an increase
in cell death. In light of these findings, the interaction of Pak1ip1
with Pak1 and the cellular events it mediates through this function
appear secondary to its role in ribosome assembly considering the
paramount cellular role of this majormetabolic activity. However,
it was not until 2011 that PAK1IP1 was confirmed as a nucleolar
protein in human cells, required for rRNA processing, and acting
as a nucleolar stress response signal with the capacity to activate
the TP53-MDM2 loop and downstream events (Yu et al., 2011).
Specifically, it was shown that both PAK1IP1 overexpression and
siRNA knockdown cause an increase in MDM2 inhibition, and
thus TP53 activation, leading to G1 cell cycle arrest and the
cessation of cell proliferation.
Our recent study in mray mice, so far the only animal model
available with loss of Pak1ip1 function, provided further insight
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FIGURE 3 | Proposed mechanism of action of Pak1ip1 in both
wild-type and homozygous manta-ray mutants. In the wild-type (left)
Pak1ip1 acts as an inhibitor of the E3 ubiquitin ligase Mdm2, which acts as
an inhibitor of Tp53 activity through an auto-regulatory feedback loop.
Mdm2 targets Tp53 for degradation by the proteasome, blocks its
transcriptional activity, and facilitates its export from the nucleus. Low
levels of Tp53 activity promote cell cycle progression at the G1 checkpoint
and cellular proliferation. In the manta-ray mutant (right) Pak1ip1 causes
altered 60S ribosome biogenesis, resulting in nucleolar stress and the
accumulation of freely circulating ribosomal proteins L5 and L11, which
inhibit Mdm2 activity. This series of events leads to an increase in Tp53
levels, G1 cell cycle arrest, and subsequent cell death, which appears to
particularly affect aspects of the cranial neural crest.
into the developmental role of this molecule (Ross et al., 2013).
Most importantly, homozygous mray mutants show an upregu-
lation of Tp53, a hallmark of ribosomopathies, while the Tp53-
Mdm2 interaction does not appear to be disrupted, as revealed by
co-immunoprecipitation experiments. Apparently Pak1ip1 loss-
of-function can adversely affect ribosome biogenesis and trigger
a Tp53 response without acting directly through Mdm2, but pre-
sumably through increases in the levels of freely circulating Rpl5
and Rpl11, which function as Mdm2 inhibitors (Figure 3).
The analysis of mray mice further added to our understand-
ing of the connections between ribosomopathies and neuro-
cristopathies with important conclusions to be drawn. First,
despite ribosome biogenesis being a ubiquitous process required
by every cell, the phenotypic outcomes by mutating individual
components of this biosynthetic machinery, which involves the
coordinated function of at least 200 proteins, can be vastly dif-
ferent. Second, neural crest-derived structures are particularly
affected by altered ribosome biogenesis, possibly due to a spe-
cific sensitivity imposed by their developmental origin. Third,
neural crest-derived structures will present with different phe-
notypic outcomes depending on which individual components
of ribosome biosynthesis are impaired. While the causes of this
variation are not understood, it is conceivable that individual sub-
populations of NCCs depend to a different degree or at different
developmental stages on ribosome biosynthesis, specific preribo-
somal and ribosomal factors are required to a different extent
by certain NCC populations, or any combination thereof. The
generation and analysis of additional animal models for ribo-
somopathies will certainly shed more light to these interesting
questions.
FUTURE DIRECTIONS AND PROPOSED EXPERIMENTS
Advancements in the understanding of how ribosomopathies
affect craniofacial development will likely come from two major
avenues of research. First, it will be necessary to determine
exactly how the composition of ribosomal proteins and associated
ribosomal cofactors change in NCCs at different developmental
stages. These studies will incorporate advanced proteomic tech-
niques capable of detecting changes in the proteome of NCCs
in order to reveal dynamic changes in ribosomal protein reg-
ulation during neural crest development. Second, the study of
suitable animal models with ribosomal disorders and associ-
ated craniofacial dysplasias will be a necessary component for
progress in the field. Tissue specific gene ablation or overexpres-
sion, directed mutagenesis, or perhaps crossing of existing animal
models would provide greater insight as to how various perturba-
tions in ribosomal function and regulation affect development of
the craniofacial structures.
In order to fully examine the role Pak1ip1 plays in cellular
function and particularly in the function of NCCs, several experi-
ments are necessary using themanta-ray mice. The establishment
of polyribosomal profiles for mutant mice and their compari-
son to controls will further illuminate the specific biosynthetic
steps impaired in the mutant. The use of either pharmacological
or genetic inhibition/downregulation of Tp53 in affected mray
mutants and the analysis of the phenotypic consequences, will
inform us as to whether the phenotypic alterations in the mutant
are exclusively a consequence of Tp53 activation. Furthermore, in
addition to measuring ribosome biosynthesis directly, it will be
pertinent to measure S6K activity as a measure of translation, as
well as to investigate the effects of amino acid treatments, such as
L-leucine on the manta-ray phenotype.
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